Trials / Not Yet Recruiting
Not Yet RecruitingNCT07464587
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Evaluation of Safety Profile in a Cohort Study of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC3721 Suspension for Inhalation | TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-02-01
- Completion
- 2027-04-01
- First posted
- 2026-03-11
- Last updated
- 2026-03-11
Locations
79 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07464587. Inclusion in this directory is not an endorsement.